ALVO icon

Alvotech

8.23 USD
-0.09
1.08%
Updated Aug 26, 10:38 AM EDT
1 day
-1.08%
5 days
-4.19%
1 month
-16.11%
3 months
-27.36%
6 months
-30.08%
Year to date
-37.46%
1 year
-29.96%
5 years
-26.45%
10 years
-26.45%
 

About: Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Employees: 1,032

0
Funds holding %
of 7,430 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

2% more funds holding

Funds holding: 50 [Q1] → 51 (+1) [Q2]

0.17% more ownership

Funds ownership: 5.52% [Q1] → 5.69% (+0.17%) [Q2]

2% less capital invested

Capital invested by funds: $159M [Q1] → $155M (-$3.72M) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 18

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$14
70%
upside
Avg. target
$14
70%
upside
High target
$14
70%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
UBS
70%upside
$14
Buy
Maintained
18 Jul 2025

Financial journalist opinion

Based on 11 articles about ALVO published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial.
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Neutral
GlobeNewsWire
5 days ago
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
REYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial.
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Neutral
GlobeNewsWire
6 days ago
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
REYKJAVIK,  ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm.
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
Neutral
Seeking Alpha
1 week ago
Alvotech (ALVO) Q2 2025 Earnings Call Transcript
Alvotech (ALVO) Q2 2025 Earnings Call Transcript
Alvotech (ALVO) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 week ago
Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates
Alvotech (ALVO) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates
Neutral
GlobeNewsWire
1 week ago
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT).
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Neutral
GlobeNewsWire
1 week ago
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT).
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 102.3% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet
Neutral
GlobeNewsWire
2 weeks ago
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025. Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday, August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). Live audio of the conference call will be webcast and available on Alvotech's investor portal.
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Neutral
GlobeNewsWire
2 weeks ago
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first half of the year ended June 30, 2025, after U.S. markets close on Wednesday, August 13, 2025.  Alvotech will also conduct a conference call to present the financial results and recent business highlights on Thursday August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).  Live audio of the conference call will be webcast and available on Alvotech's investor portal.
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Charts implemented using Lightweight Charts™